患有非功能性垂体瘤的患者死亡率增加:三级中心的研究
在PubMed上查看摘要
概括
此摘要是机器生成的。患有非功能性垂体腺瘤 (NFPA) 的患者的死亡率高于一般人群. 这些患者的高血压和多次手术增加了死亡风险.
科学领域
- 内分泌学
- 癌症学
- 流行病学
背景情况
- 在非功能性垂体腺瘤 (NFPA) 研究中,关于死亡率和存活率的结果往往是异质和矛盾的.
- 关于NFPA患者预测结果的数据有限.
研究的目的
- 分析749名被诊断为NFPA的患者的生存率.
- 为了确定与普通人群相比的死亡风险.
- 确定NFPA患者死亡率的预测因素.
主要方法
- 从2007年3月到2023年8月对749名NFPA患者的回顾性分析.
- 对墨西哥人口的标准化死亡率 (SMR) 的计算.
- 使用了生存分析和Cox比例危险 (HR) 模型.
主要成果
- 与一般人群相比,NFPA患者的整体死亡风险显著增加 (SMR 8. 86).
- 年轻患者 (< 60 岁),男性和女性的死亡风险较高.
- 动脉高血压 (HR 2. 19) 和手术总数 (HR 1.32) 是死亡率的重要预测因素.
结论
- 与一般人群相比,NFPA患者的死亡率增加.
- 动脉高血压和多次手术与NFPA患者死亡的可能性较高有关.
相关概念视频
Hormones, the biochemical messengers produced by endocrine glands, are pivotal in regulating bodily functions and maintaining homeostasis. Each hormone's balance is crucial; imbalances can lead to significant physiological disruptions. Major hormones include oxytocin, cortisol, epinephrine, estrogen, testosterone, thyroxine, growth hormone, insulin, and glucagon.
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and...
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...

